At the 20th Congress of the European Hematology Association (EHA), Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the University of Southampton, Southampton, UK, provides an update on the safety results of the phase 3 SABRINA study, which is comparing subcutaneous and intravenous rituximab in the maintenance setting of patients with follicular lymphoma.
SABRINA: Phase 3 study comparing subcutaneous and intravenous rituximab in follicular lymphoma
3rd July 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now